Recent clinical studies of the immunomodulatory drug (IMiD®) lenalidomide

被引：50

作者：

Bartlett, JB ^{[1
]}

Tozer, A ^{[1
]}

Stirling, D ^{[1
]}

Zeldis, JB ^{[1
]}

机构：

[1] Celgene Corp, Summit, NJ 07901 USA

来源：

BRITISH JOURNAL OF CANCER | 2005年 / 93卷 / 06期

关键词：

lenalidomide; thalidomide; multiple myeloma; myelodysplastic syndromes; immunomodulatory; angiogenesis;

D O I：

10.1038/sj.bjc.6602774

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Thalidomide is effective in the treatment of multiple myeloma. The immunomodulatory drug and thalidomide analogue lenalidomide is currently in late stage clinical development for MDS and multiple myeloma. This minireview highlights the course of initial and ongoing lenalidomide clinical development in oncology with reference to earlier thalidomide studies.

引用

收藏

页码：613 / 619

页数：7

相关论文

共 37 条

[1] Phase 1 study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers [J].

Bartlett, JB ;

Michael, A ;

Clarke, IA ;

Dredge, K ;

Nicholson, S ;

Kristeleit, H ;

Polychronis, A ;

Pandha, H ;

Muller, GW ;

Stirling, DI ;

Zeldis, J ;

Dalgleish, AG .

BRITISH JOURNAL OF CANCER, 2004, 90 (05) :955-961

[2] Timeline - The evolution of thalidomide and its IMiD derivatives as anticancer agents [J].

Bartlett, JB ;

Dredge, K ;

Dalgleish, AG .

NATURE REVIEWS CANCER, 2004, 4 (04) :314-322

[3]

Baz R, 2004, BLOOD, V104, p658A

[4] Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer [J].

Dahut, WL ;

Gulley, JL ;

Arlen, PM ;

Liu, Y ;

Fedenko, KM ;

Steinberg, SM ;

Wright, JJ ;

Parnes, H ;

Chen, CC ;

Jones, E ;

Parker, CE ;

Linehan, WM ;

Figg, WD .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (13) :2532-2539

[5] Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma [J].

Davies, FE ;

Raje, N ;

Hideshima, T ;

Lentzsch, S ;

Young, G ;

Tai, YT ;

Lin, B ;

Podar, K ;

Gupta, D ;

Chauhan, D ;

Treon, SP ;

Richardson, PG ;

Schlossman, RL ;

Morgan, GJ ;

Muller, GW ;

Stirling, DI ;

Anderson, KC .

BLOOD, 2001, 98 (01) :210-216

[6] Primary treatment with pulsed melphalan, dexamethasone, thalidomide (MDT) for symptomatic patients with multiple myeloma ≥ 75 years of age. [J].

Dimopoulos, MA ;

Repoussis, P ;

Terpos, E ;

Kyrtsonis, MC ;

Zomas, A ;

Katodritou, E ;

Delibasi, S ;

Vassou, A ;

Anagnostopoulos, A ;

Pouli, A ;

Zervas, K ;

Margaritis, D ;

Anagnostopoulos, N ;

Maniatis, AG .

BLOOD, 2004, 104 (11) :414A-414A

[7] Treatment of Waldenstrom's macroglobulinemia with single-agent thalidomide or with the combination of clarithromycin, thalidomide and dexamethasone [J].

Dimopoulos, MA ;

Tsatalas, C ;

Zomas, A ;

Hamilos, G ;

Panayiotidis, P ;

Margaritis, D ;

Matsouka, C ;

Economopoulos, T ;

Anagnostopoulos, N .

SEMINARS IN ONCOLOGY, 2003, 30 (02) :265-269

[8]

DIMPOULOS M, 2005, HAEMATOLOGICA HEM S2, V90, P160

[9] Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects [J].

Dredge, K ;

Marriott, JB ;

Macdonald, CD ;

Man, HW ;

Chen, R ;

Muller, GW ;

Stirling, D ;

Dalgleish, AG .

BRITISH JOURNAL OF CANCER, 2002, 87 (10) :1166-1172

[10] Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity [J].

Dredge, K ;

Marriott, JB ;

Todryk, SM ;

Muller, GW ;

Chen, R ;

Stirling, DI ;

Dalgleish, AG .

JOURNAL OF IMMUNOLOGY, 2002, 168 (10) :4914-4919

← 1 2 3 4 →